Over 160 therapeutic and in vivo diagnostic monoclonal antibodies have been approved by
the US FDA since the first monoclonal antibody, muromonab, was approved in 1986 …

Immunoglobulin G (IgG) antibodies are a critical component of the adaptive immune system,
binding to and neutralizing pathogens and other foreign substances. Recent advances in …

Abstract mAbs are highly indispensable tools for diagnostic, prophylactic, and therapeutic
applications. The first technique, hybridoma technology, was based on fusion of B …

Antibody effector functions including antibody-dependent cellular cytotoxicity (ADCC) and
phagocytosis (ADCP) are mediated through the interaction of the antibody Fc region with …

The global impact of zoonotic viral outbreaks underscores the pressing need for innovative
antiviral strategies, particularly against respiratory zoonotic RNA viruses. These viruses …

Adaptive immunity to viral infections requires time to neutralize and clear viruses to resolve
infection. Fast growing and pathogenic viruses are quickly established, are highly …

There is tremendous interest in the production of recombinant proteins, particularly bispecific
antibodies and antibody–drug conjugates for research and therapeutic use. Here, we …

Monoclonal antibodies in the prophylaxis and treatment of COVID-19 have been crucial in
reducing severe infections when vaccines were unavailable. However, as the virus and its …